The clinical and economic benefits of GnRH agonist in treating endometriosis.

Mark Glasser, M Glasser
The American journal of managed care · 1999 · vol. 5(5 Suppl) , pp. S316–26 · PMID:10537664 · W2416325916
other OA: closed CC0 ⤵ 3 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper evaluates the clinical and economic advantages of using GnRH agonists for endometriosis treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715mesh:D017699endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Health Care Costs Pelvic Pain Treatment Outcome Algorithms Cost Savings Endometriosis Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone Health Maintenance Organizations Health Maintenance Organizations Health Maintenance Organizations Humans Hysteroscopy Hysteroscopy Infertility, Female Male

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (3)

Cited by (3)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:24.024533+00:00
License: CC0 · commercial use OK